The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end point but reduced neurotoxicity.
Matt Flowers
Advertisement
Articles by Matt Flowers
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Durability of PFS and OS Benefit vs. Historical Control
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
Opamtistomig Earns FDA Fast Track in First-Line Biliary Tract Cancer
4
How Disease Burden Shapes First-Line RCC Treatment Selection
5